Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma

Samantha Pozzi, Alessia Bari, Martin Pecherstorfer, Sonia Vallet

Research output: Journal article (peer-reviewed)Review article

5 Citations (Scopus)

Abstract

Relapsed/refractory (RR) multiple myeloma (MM) patients are a fragile population because of prolonged drug exposure and advanced age. Preserving a good quality of life is of high priority for these patients and the treatment of disease- and treatment-related complications plays a key role in their management. By preventing and limiting MM-induced complications, supportive care improves patients' outcome. Erythropoietin-stimulating agents and bisphosphonates are well-established supportive strategies, yet novel agents are under investigation, such as anabolic bone agents and activin receptor-like kinase (ALK) inhibitors. The recent dramatic changes in the treatment landscape of MM pose an additional challenge for the routine care of RRMM patients. Multidrug combinations in first and later lines increase the risk for long-lasting toxicities, including adverse cardiovascular and neurological events. Moreover, recently approved first-in-class drugs have unique side-effect profiles, such as ocular toxicity of belantamab mafodotin or gastrointestinal toxicity of selinexor. This review discusses current standards in supportive treatment of RRMM patients, including recommendations in light of the recent SARS-CoV-19 pandemic, and critically looks at the incidence and management of side effects of standard as well as next generation anti-MM agents.

Original languageEnglish
Article number4978
JournalCancers
Volume13
Issue number19
DOIs
Publication statusPublished - 01 Oct 2021

Fingerprint

Dive into the research topics of 'Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma'. Together they form a unique fingerprint.

Cite this